US · INDV
Indivior Pharmaceuticals Inc
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- North Chesterfield, VA 23235
- Website
- indivior.com
Price · as of 2025-12-31
$37.66
Market cap 4.08B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $114.22 | +203.29% |
| Intrinsic Value(DCF) | $46.37 | +23.13% |
| Graham-Dodd Method(GD) | $7.59 | -79.84% |
| Graham Formula(GF) | $20.41 | -45.81% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $20.25 | ||||
| 2017 | $27.75 | $69.96 | $107.21 | $0.70 | $10.87 |
| 2018 | $7.05 | $59.00 | $1.43 | $9.48 | $0.00 |
| 2019 | $3.10 | $55.07 | $1.73 | $6.02 | $0.00 |
| 2020 | $8.27 | $46.55 | $0.00 | $0.00 | $8.79 |
| 2021 | $17.05 | $96.02 | $1.04 | $8.43 | $41.33 |
| 2022 | $17.75 | $46.63 | $0.00 | $0.00 | $0.00 |
| 2023 | $21.30 | $74.07 | $54.79 | $0.00 | $0.00 |
| 2024 | $9.70 | $44.08 | $25.63 | $0.00 | $0.25 |
| 2025 | $31.98 | $114.22 | $36.50 | $7.59 | $20.41 |
AI valuation
Our deep-learning model estimates Indivior Pharmaceuticals Inc's (INDV) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $114.22
- Current price
- $37.66
- AI upside
- +203.29%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$46.37
+23.13% upside
Graham-Dodd
$7.59
-79.84% upside
Graham Formula
$20.41
-45.81% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INDV | Indivior Pharmaceuticals … | $37.66 | 4.08B | +203% | +23% | -80% | -46% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ADMA | ADMA Biologics, Inc. | $15.57 | 3.71B | +161% | +134% | -67% | +6% | 26.89 | 8.28 | 7.74 | 19.93 | — | 8.35 | 57.39% | 37.53% | 28.80% | 35.56% | 38.62% | 26.40% | 0.17 | 26.93 | 6.71 | 3.54 | -0.04 | -2593.00% | 1963.00% | -7473.00% | 0.70% | 0.72 | 6.98% | 0.00% | 0.00% | 0.81% | 20.60 | 141.74 | 7.73 | 18.36 |
| AMRX | Amneal Pharmaceuticals, I… | $13.81 | 4.34B | +181% | -25% | -85% | -74% | 59.88 | 4.86 | 1.43 | -793.31 | — | -15.90 | 36.88% | 14.02% | 2.39% | 18.52% | 25.08% | 2.01% | 0.14 | 1.75 | 2.17 | 1.34 | 30.17 | -15789.00% | 805.00% | 2263.00% | 6.26% | 0.39 | 17.41% | 0.00% | 0.00% | 61.20% | 9.83 | 15.40 | 1.38 | 2.26 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| HNGE | Hinge Health, Inc. | $42.76 | 3.37B | +11% | +616% | — | — | -6.72 | 9.38 | 6.04 | -5.91 | -0.20 | 11.39 | 79.65% | -92.94% | -89.86% | -132.86% | 6793.55% | -74.51% | 0.02 | — | 1.47 | 1.19 | 0.37 | 336000.00% | 5058.00% | 27749.00% | 4.81% | 0.47 | -2122.88% | 0.00% | 0.00% | 1.83% | -5.85 | 18.72 | 5.44 | 2.49 |
| LNTH | Lantheus Holdings, Inc. | $74.91 | 5.09B | +40% | +25% | -60% | -60% | 22.05 | 4.73 | 3.34 | 14.36 | — | 40.39 | 61.10% | 20.16% | 15.15% | 21.45% | 30.32% | 11.10% | 0.00 | 15.74 | 2.70 | 2.15 | -1.07 | -2179.00% | 50.00% | -2820.00% | 6.88% | 1.17 | 46.40% | 0.00% | 0.00% | 1.26% | 15.41 | 13.53 | 3.11 | 4.60 |
| OPCH | Option Care Health, Inc. | $32.46 | 5.27B | +26% | -61% | -85% | -17% | 24.09 | 3.77 | 0.89 | 10.05 | 592.65 | -16.55 | 19.26% | 5.98% | 3.67% | 15.20% | 15.01% | 6.04% | 0.00 | 2.70 | 1.53 | 0.85 | -0.49 | 407.00% | 1303.00% | -1019.00% | 5.17% | 0.31 | 15.65% | 0.00% | 0.00% | 26.95% | 14.11 | 18.45 | 0.84 | 3.52 |
| PRAX | Praxis Precision Medicine… | $336.75 | 7.12B | -61% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
| VKTX | Viking Therapeutics, Inc. | $33.84 | 3.91B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
- CEO
- Joseph J. Ciaffoni
- Employees
- 1.03K
- Beta
- 1.00
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($46.37 ÷ $37.66) − 1 = +23.13% (DCF, example).